Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon.
Arjun Khunger(Cleveland Clinic), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Jane Gao(Navidea Biopharmaceuticals (United States)), Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Christian Laing(Lineage Cell Therapeutics (United States)), Jenn Tsau(Navidea Biopharmaceuticals (United States)), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Anil Pahuja(Lineage Cell Therapeutics (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Zeni Alfonso(Lineage Cell Therapeutics (United States)), Ghanashyam Sarikonda(Novartis (United States))
Cited by 2
Related Papers
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
|Nature Reviews Clinical Oncology|2016|1.1k
Antibody validation
|BioTechniques|2010|601
Linear Motif Atlas for Phosphorylation-Dependent Signaling
|Science Signaling|2008|465